Dovitinib (TKI258) and Abiraterone Acetate in Metastatic Castrate-Resistant Prostate Cancer (mCRPC)

PHASE2TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 19, 2014

Primary Completion Date

June 5, 2017

Study Completion Date

June 5, 2017

Conditions

Prostate Cancer

Interventions

DRUG

Dovitinib

Starting dose will be 400 mg by mouth daily on Days 1-5, 8-12, 15-19, and 22-26 of each 28 day cycle.

DRUG

Abiraterone Acetate

4 tablets (250 mg each) by mouth daily.

DRUG

Prednisone

5 mg by mouth twice daily.

Trial Locations (1)

University of Texas MD Anderson Cancer Center, Houston